Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(2.31)
# 2,578
Out of 5,173 analysts
115
Total ratings
43.56%
Success rate
-2.34%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STOK Stoke Therapeutics | Maintains: Buy | $36 → $60 | $33.40 | +79.64% | 6 | Mar 20, 2026 | |
| MPLT MapLight Therapeutics | Initiates: Buy | $35 | $17.16 | +103.96% | 1 | Mar 19, 2026 | |
| CLNN Clene | Maintains: Buy | $48 | $5.67 | +746.56% | 7 | Mar 13, 2026 | |
| CMPS COMPASS Pathways | Maintains: Buy | $15 → $20 | $5.34 | +274.53% | 5 | Feb 18, 2026 | |
| BIIB Biogen | Maintains: Buy | $220 → $230 | $183.64 | +25.25% | 22 | Feb 9, 2026 | |
| GHRS GH Research | Maintains: Buy | $35 → $39 | $13.21 | +195.23% | 5 | Jan 6, 2026 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $25 → $24 | $9.42 | +154.78% | 7 | Nov 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $160 → $164 | $127.05 | +29.08% | 17 | Oct 29, 2025 | |
| ATAI AtaiBeckley | Maintains: Buy | $11 → $14 | $3.39 | +312.98% | 4 | Oct 22, 2025 | |
| ANVS Annovis Bio | Maintains: Buy | $17 | $2.50 | +580.00% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $27 | $4.02 | +571.64% | 6 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $3.88 | +209.28% | 5 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $112 → $80 | $1.47 | +5,342.18% | 7 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $33 | $20.99 | +57.22% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $101 → $150 | $8.74 | +1,616.25% | 4 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $28.77 | - | 2 | Jan 31, 2017 |
Stoke Therapeutics
Mar 20, 2026
Maintains: Buy
Price Target: $36 → $60
Current: $33.40
Upside: +79.64%
MapLight Therapeutics
Mar 19, 2026
Initiates: Buy
Price Target: $35
Current: $17.16
Upside: +103.96%
Clene
Mar 13, 2026
Maintains: Buy
Price Target: $48
Current: $5.67
Upside: +746.56%
COMPASS Pathways
Feb 18, 2026
Maintains: Buy
Price Target: $15 → $20
Current: $5.34
Upside: +274.53%
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $220 → $230
Current: $183.64
Upside: +25.25%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $39
Current: $13.21
Upside: +195.23%
Zevra Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $25 → $24
Current: $9.42
Upside: +154.78%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Buy
Price Target: $160 → $164
Current: $127.05
Upside: +29.08%
AtaiBeckley
Oct 22, 2025
Maintains: Buy
Price Target: $11 → $14
Current: $3.39
Upside: +312.98%
Annovis Bio
Sep 30, 2025
Maintains: Buy
Price Target: $17
Current: $2.50
Upside: +580.00%
Jul 29, 2025
Maintains: Buy
Price Target: $21 → $27
Current: $4.02
Upside: +571.64%
Mar 13, 2025
Maintains: Buy
Price Target: $14 → $12
Current: $3.88
Upside: +209.28%
Jan 6, 2025
Maintains: Buy
Price Target: $112 → $80
Current: $1.47
Upside: +5,342.18%
Mar 12, 2024
Maintains: Buy
Price Target: $40 → $33
Current: $20.99
Upside: +57.22%
Aug 3, 2021
Maintains: Buy
Price Target: $101 → $150
Current: $8.74
Upside: +1,616.25%
Jan 31, 2017
Upgrades: Buy
Price Target: n/a
Current: $28.77
Upside: -